-
-
-
-
-
-
-
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
-
-
-
-
-
-
-
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
-
-
-
-
-
-
-
Astrellas and Pfizer's (PFE) announces results from Phase 3 study on XTANDI
-
-
-
-
-
-
-
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
-
-
-
-
-
-
-
Astellas Completes Acquisition of Propella Therapeutics
-
-
-
-
-
-
-
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
-
-
-
-
-
-
-
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
-
1,211,968 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

